Imikeraderm

Imiquimod, the active ingredient in Imikeraderm, is an immune response modifier presented as a topical formulation for skin application. It stimulates local immune activity to treat actinic keratosis, superficial basal cell carcinoma, and external genital warts in adult patients.

GNH USA supplies Imikeraderm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable logistics and documentation support.

Imikeraderm (imiquimod) is employed in dermatologic conditions where immune activation aids lesion clearance. - Actinic keratosis: reduces dysplastic skin lesions and prevents progression to squamous cell carcinoma. - Superficial basal cell carcinoma: promotes tumor regression through local immune response. - External genital warts: clears human papillomavirus‑induced lesions by enhancing antiviral immunity.

Topical imiquimod may cause local and systemic adverse reactions, most of which are mild to moderate.

Common Side Effects: - Redness: localized erythema at the application site. - Itching: mild pruritus. - Burning sensation: transient stinging feeling.

Serious or Rare Side Effects: - Severe skin reaction: ulceration or necrosis of treated skin. - Allergic contact dermatitis: widespread rash with swelling. - Systemic flu‑like symptoms: fever, chills, fatigue.

When using Imikeraderm, clinicians should consider several safety precautions to minimize adverse events. - Assess skin integrity: avoid application on broken or infected skin. - Limit exposure: apply only to prescribed area and follow recommended frequency. - Monitor for irritation: discontinue if severe local reaction develops. - Caution in immunocompromised patients: increased risk of infection. - Avoid use during pregnancy and lactation unless benefits outweigh risks. - Store at room temperature: keep in original container, protect from moisture and light.

Imiquimod can interact with other topical agents and systemic medications that affect immune function.

Major Interactions (Avoid): - Concurrent use of other topical irritants: may exacerbate skin inflammation. - Systemic immunosuppressants: reduce therapeutic efficacy of imiquimod.

Moderate Interactions (Monitor Closely): - Antiviral agents: potential additive immune effects. - Vaccines: topical imiquimod may enhance local immune response to live vaccines. - Phototherapy: increased risk of skin irritation when combined.